Skip to Main Content

Paper Details

Bevacizumab beyond Progression for Newly Diagnosed Glioblastoma (BIOMARK): Phase II Safety, Efficacy and Biomarker Study.
Cancers (Basel)
3
2022
Author NameAffiliation
Motoo NaganeKyorin University Faculty of Medicine
Tatsuhiro ShibataNational Cancer Center Research Institute
Ryo NishikawaSaitama Medical University International Medical Center
  • 1 - 3

Datasets

Release 1.2